LONDON, Sept 20 (Reuters) - Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie’s $18-billion-a-year biologic drug Humira, the world’s best-selling prescription medicine.
Their version of the product, which is set for launch in Europe on or after Oct. 16, is the fifth so-called biosimilar copy of Humira. The large number of copies reflects intense competition among rivals for a slice of a huge market.
Amgen, Novartis’s generics wing Sandoz, South Korea’s Samsung Bioepis and Germany’s Boehringer Ingelheim have already won approval for four other biosimilars to Humira.
Humira is used to treat a range of conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. (Reporting by Ben Hirschler; editing by Jason Neely)